Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


28.11.2022

2 BMC Cancer
2 Br J Cancer
2 Gastrointest Endosc
2 Head Neck
2 Int J Radiat Oncol Biol Phys
2 J Clin Endocrinol Metab
1 J Laryngol Otol
1 J Nucl Med
1 Oral Oncol
1 Proc Natl Acad Sci U S A
1 Radiology
1 Radiother Oncol
1 Surgery


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. YANG Y, Tang P, Ma M, Zhang H, et al
    Comparison of clinicopathological features and prognostic significance between synchronous multiple primary and solitary esophageal squamous cell carcinomas.
    BMC Cancer. 2022;22:1191.
    PubMed         Abstract available

  2. YEH TL, Hsu MS, Hsu HY, Tsai MC, et al
    Risk of cardiovascular diseases in cancer patients: A nationwide representative cohort study in Taiwan.
    BMC Cancer. 2022;22:1198.
    PubMed         Abstract available


    Br J Cancer

  3. XUE L, Zhao Z, Wang M, Ma L, et al
    A liquid biopsy signature predicts lymph node metastases in T1 oesophageal squamous cell carcinoma: implications for precision treatment strategy.
    Br J Cancer. 2022;127:2052-2059.
    PubMed         Abstract available

  4. ZAIDI AH, Pratama MY, Omstead AN, Gorbonova A, et al
    A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.
    Br J Cancer. 2022;127:2016-2024.
    PubMed         Abstract available


    Gastrointest Endosc

  5. MCDONALD OG, Montgomery EA
    Artificial intelligence for dysplasia grading in Barrett's esophagus: hematoxylin and eosin is here to stay.
    Gastrointest Endosc. 2022;96:926-928.
    PubMed        

  6. FAGHANI S, Codipilly DC, David Vogelsang, Moassefi M, et al
    Development of a deep learning model for the histologic diagnosis of dysplasia in Barrett's esophagus.
    Gastrointest Endosc. 2022;96:918-925.
    PubMed         Abstract available


    Head Neck

  7. BLAKE CL, Brown TE, Pelecanos A, Moroney LB, et al
    Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity-modulated radiotherapy with concurrent chemotherapy.
    Head Neck. 2022 Nov 25. doi: 10.1002/hed.27249.
    PubMed         Abstract available

  8. WANG Y, Zhang L, Zhang T, Jin S, et al
    Predictive effect of pretreatment nutritional risk and GLIM-defined malnutrition on the nutrition impact symptom clusters in patients with head and neck cancer undergoing radiotherapy.
    Head Neck. 2022 Nov 23. doi: 10.1002/hed.27250.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  9. QIAN DC, Ulrich BC, Peng G, Zhao H, et al
    Outcomes stratification of head and neck cancer using pre- and post-treatment DNA methylation from peripheral blood.
    Int J Radiat Oncol Biol Phys. 2022 Nov 18:S0360-3016(22)03521.
    PubMed         Abstract available

  10. YOU J, Zhu S, Li J, Li J, et al
    High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial.
    Int J Radiat Oncol Biol Phys. 2022 Nov 16:S0360-3016(22)03520.
    PubMed         Abstract available


    J Clin Endocrinol Metab

  11. WANG X, Zheng X, Zhu J, Li Z, et al
    Radioactive iodine therapy does not improve cancer-specific survival in Hurthle cell carcinoma of the thyroid.
    J Clin Endocrinol Metab. 2022 Jul 31. pii: 6652584. doi: 10.1210.
    PubMed         Abstract available

  12. PALERMO A, Cesareo R
    Response to Letter to the Editor from Xu and Yang: Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules:12-Month Results of a Randomized Trial (LARA II Study).
    J Clin Endocrinol Metab. 2022 Sep 3. pii: 6691130. doi: 10.1210.
    PubMed        


    J Laryngol Otol

  13. ARORA A, Brunet A, Oikonomou G, Tornari C, et al
    Establishing and integrating a transoral robotic surgery programme into routine oncological management of head and neck cancer - a UK perspective - ERRATUM.
    J Laryngol Otol. 2022 Nov 22:1. doi: 10.1017/S0022215122002249.
    PubMed        


    J Nucl Med

  14. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed         Abstract available


    Oral Oncol

  15. LIU HC, Williamson CW, Zou J, Todd JR, et al
    Quantitative prediction of aspiration risk in head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2022;136:106247.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  16. ZHAO X, Cohen EEW, William WN Jr, Bianchi JJ, et al
    Somatic 9p24.1 alterations in HPV(-) head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.
    Proc Natl Acad Sci U S A. 2022;119:e2213835119.
    PubMed         Abstract available


    Radiology

  17. TAKAMATSU A, Yoshida K, Toshima F, Kozaka K, et al
    Single-Center Analysis of Pegfilgrastim-induced Aortitis Using a Drug Prescription Database and CT Findings.
    Radiology. 2022 Aug 9:220357. doi: 10.1148/radiol.220357.
    PubMed         Abstract available


    Radiother Oncol

  18. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
    Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
    Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
    PubMed         Abstract available


    Surgery

  19. WALLER GC, Patel DJ, Baker MS
    Early-stage gastric and gastroesophageal junction cancer: Is there a survival benefit to neoadjuvant therapy?
    Surgery. 2022;172:1753-1758.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: